The category
that changed
everything.

Compounded GLP-1 telehealth went from regulatory experiment to consumer product faster than almost any category in healthcare history. Three years ago, the words "compounded semaglutide" appeared in roughly 200 monthly Google searches. Last month, that number was over 600,000. The infrastructure to support that traffic — telehealth platforms, compounding pharmacies, patient-facing brands — was assembled in real time, often by people who weren't healthcare operators six months earlier.

That history matters because the category is still volatile. Providers come and go. Pharmacies switch suppliers. The FDA's drug shortage list — the regulatory mechanism that determines which compounds can be prepared under specific exemptions — is dynamic, and its updates ripple through the entire market within weeks.

Compounded vs branded — the legal context.

The most common confusion among patients we've spoken with: thinking that compounded semaglutide and Ozempic are the same product. They contain the same active ingredient, but they are not the same product, and the difference matters legally.

Branded GLP-1s — Ozempic, Wegovy, Mounjaro, Zepbound — are FDA-approved. They are manufactured under specific GMP standards, undergo defined safety and efficacy review, and ship with a precise label. Compounded versions are prepared by state-licensed compounding pharmacies under regulatory exemptions that exist when the FDA designates a drug as being in shortage. They are not FDA-approved. They have not undergone the same manufacturing or efficacy review. This is not a problem in itself — compounding is a legitimate, long-established practice — but it means the product you receive depends heavily on which pharmacy fills it.

The pharmacy matters more than the brand. Ask your provider where it's compounded — and if they hedge on the answer, find another provider.

What changed with the FDA shortage list updates.

In late 2024 and again in early 2026, the FDA updated its drug shortage list, removing certain GLP-1 medications. The practical effect: providers that had been compounding tirzepatide had to pause or withdraw within weeks. Hims, Mochi, and Henry Meds responded differently — Hims withdrew compounded tirzepatide entirely; Henry Meds maintained it under different regulatory provisions; Mochi paused and resumed selectively.

For patients, this meant active prescriptions sometimes had to be migrated mid-protocol — never an ideal scenario clinically. If you're starting a GLP-1 protocol now, the practical implication is that tirzepatide compounded availability is less stable than semaglutide, and the provider's ability to continue your prescription depends partly on regulatory factors outside their control.

What we'd be cautious about.

Three things we'd ask any patient considering a compounded GLP-1 to think about, in this order:

First, the pharmacy. A reputable provider should be able to tell you which compounding pharmacy is filling your prescription, and that pharmacy should be state-licensed and ideally PCAB-accredited. If the answer to "where is this compounded" is vague, that's a signal.

Second, the cost trajectory. Most providers price the entry-level dose attractively (sub-$200) and increase pricing meaningfully as your dose escalates. Read the dose-by-dose pricing before you commit. Some providers — Hims is one — offer flat pricing across all dose levels for a 6-month commitment. That can be the better deal long-term, but only if you're confident you'll stay on the protocol.

Third, your exit plan. GLP-1 weight loss is largely durable while you're on the medication and partially reversible after stopping. The clinical question is not just "will this work" but "what's the maintenance plan." Providers vary substantially in how they support taper, maintenance dosing, and post-medication weight stability. Ask. The answer reveals whether they're running a subscription business or a clinical practice.